<DOC>
	<DOCNO>NCT01423695</DOCNO>
	<brief_summary>The 3 weekly combination trastuzumab paclitaxel approve treatment advance breast cancer base large pivotal study . However , mono combination chemotherapy trial suggest weekly paclitaxel well therapeutic index , especially palliative setting . The present trial examines efficacy safety weekly paclitaxel limited duration combine continue trastuzumab HER2+ patient .</brief_summary>
	<brief_title>Weekly Paclitaxel Trastuzumab Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>histologically confirm metastatic breast cancer overexpressing HER2 pretreatment anthracycline either adjuvant palliative setting . HER2 positivity define 2+ 3+ overexpression use DAKO HercepTest , confirm fluorescence insitu hybridization ( FISH ) 2+ . inform consent 1 chemotherapy advance disease taxane trastuzumab pretreatment brain metastasis Eastern Cooperative Oncology Group ( ECOG ) performance status &gt; 1 pregnancy lactation , childbearing potential without reliable contraception clinically significant cardiac disease , neutrophils &lt; 1500/µl , platelet &lt; 75,000/µl total bilirubin creatinine &gt; 1.5 × upper limit normal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>